When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Turn A Profit?
When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Turn A Profit?
We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) business as it appears the company may be on the cusp of a considerable accomplishment. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. With the latest financial year loss of US$1.1b and a trailing-twelve-month loss of US$510m, the US$24b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Alnylam Pharmaceuticals' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
我们认为现在是分析Alnylam Pharmicals, Inc.的好时机。”s(纳斯达克股票代码:ALNY)的业务看来该公司可能正处于取得重大成就的风口浪尖。Alnylam Pharmaceuticals, Inc. 是一家生物制药公司,专注于发现、开发和商业化基于核糖核酸干扰的新疗法。这家市值240亿美元的公司最近一个财年的亏损为11亿美元,过去十二个月的亏损为5.1亿美元,通过接近盈亏平衡的目标来缓解亏损。投资者最紧迫的担忧是Alnylam Pharmaceuticals的盈利之路——它何时会实现盈亏平衡?我们简要概述了行业分析师对该公司、盈亏平衡年份和隐含增长率的预期。
See our latest analysis for Alnylam Pharmaceuticals
查看我们对 Alnylam Pharmicals 的最新分析
Alnylam Pharmaceuticals is bordering on breakeven, according to the 27 American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$292m in 2026. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 58%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
27位美国生物技术分析师表示,Alnylam Pharmicals接近盈亏平衡。他们预计,该公司将在2025年蒙受最终亏损,然后在2026年产生2.92亿美元的正利润。因此,预计该公司将在大约两年后实现盈亏平衡。为了在这一天实现盈亏平衡,公司必须同比增长多少?使用最适合的线,我们计算出平均年增长率为58%,这相当乐观!如果事实证明这个利率过于激进,该公司的盈利时间可能比分析师预测的要晚得多。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240114/0-2ab0c4b4a55bc00f4bc86b77f9fa35f2-0-82277a3c974bed17fee6f98e2d590901.png/big)
We're not going to go through company-specific developments for Alnylam Pharmaceuticals given that this is a high-level summary, though, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
鉴于这是一个高层次的摘要,我们不打算详细介绍Alnylam Pharmicals的公司具体发展情况,但要考虑到生物技术公司的现金流通常不稳定,这取决于公司所处的产品类型和开发阶段。这意味着高增长率并不罕见,尤其是在公司目前处于投资期的情况下。
Before we wrap up, there's one issue worth mentioning. Alnylam Pharmaceuticals currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. Oftentimes, losses exist only on paper but other times, it can be a red flag.
在我们总结之前,有一个问题值得一提。Alnylam制药公司目前的资产负债表上有负资产。用于处理一段时间内累积的损失的会计方法可能会导致这种情况的发生。这是因为负债会结转到未来,直到注销。通常,损失只存在于纸面上,但有时可能是一个危险信号。
Next Steps:
后续步骤:
This article is not intended to be a comprehensive analysis on Alnylam Pharmaceuticals, so if you are interested in understanding the company at a deeper level, take a look at Alnylam Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should further examine:
本文无意对Alnylam Pharmicals进行全面分析,因此,如果你有兴趣更深入地了解该公司,请查看Alnylam Pharmaceuticals在Simply Wall St上的公司页面。我们还整理了一份相关因素清单,你应该进一步研究:
- Valuation: What is Alnylam Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Alnylam Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Alnylam Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Alnylam Pharmicals 今天的价值是多少?价格中是否已经考虑了未来的增长潜力?我们的免费研究报告中的内在价值信息图有助于可视化Alnylam Pharmicals目前是否被市场定价错误。
- 管理团队:一支经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Alnylam Pharmicals董事会成员以及首席执行官的背景。
- 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在此处浏览我们的免费这些优质股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。